Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) – The German Adjuvant Breast Cancer Group☆
Full Text Available
☆ This report presents the final analysis of trial GABG-IV E-93. Preliminary results were reported at the ASCO Annual Meeting in 2001.
PII: S0959-8049(09)00726-6
doi:10.1016/j.ejca.2009.10.001
© 2009 Elsevier Ltd. All rights reserved.

